Literature DB >> 22215258

Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-β1.

Fang Fan1, Yuehua Li, Xuanchu Duan, Tantai Zhao, Dongning Pan, Huihui Chen.   

Abstract

PURPOSE: To investigate the influence of rosiglitazone on activation of human Tenon's fibroblasts (HTFs) and to access the possible mechanism.
METHODS: Cultured human Tenon's fibroblasts were pretreated in two different concentrations of rosiglitazone (5 μmol/l and 10 μmol/l) before being stimulated with 5 ng/ml transforming growth factor β1 (TGF-β1). The viability and proliferation of cells were accessed by cell count kit-8 assay; Cell migration was examined by the wound closure assay; Alpha smooth muscle actin (α-SMA), connective tissue growth factor (CTGF) and type I collagen (COL I) transcription were detected by RT-qPCR; The expression and localization of α-SMA protein were examined by Western-blot analysis and Immunofluorescence staining; Western-blot analysis was also used to check the expression of CTGF, COL I peroxisome proliferator-activated receptor gamma (PPAR-γ), and phosphorylation of the signaling protein Smad2/3
RESULTS: Rosiglitazone is able to attenuate the up-regulation of α-SMA, CTGF, and COL I transcription, as well as affect protein expression, proliferation, and migration of cells; rosiglitazone also can increase PPAR-γ expression and attenuate Smad2/3 phosphorylation.
CONCLUSIONS: Rosiglitazone can effectively attenuate activation of HTFs induced by TGF-β1 without obvious toxicity. The possible mechanism might be that rosiglitazone interferes with TGF-β/Smad signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215258     DOI: 10.1007/s00417-011-1903-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  27 in total

Review 1.  A major review of antimetabolites in glaucoma therapy.

Authors:  S C Loon; P T Chew
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

2.  Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.

Authors:  Jun Yu; Sui Zhang; Eagle S H Chu; Minnie Y Y Go; Rebecca H Y Lau; Junhong Zhao; Chung-Wah Wu; Lixin Tong; Jingmin Zhao; Terence C W Poon; Joseph J Y Sung
Journal:  Int J Biochem Cell Biol       Date:  2010-02-13       Impact factor: 5.085

3.  Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts.

Authors:  Guo-You Zhang; Tao Cheng; Ming-Hua Zheng; Cheng-Gang Yi; Hua Pan; Zhi-Jie Li; Xing-Long Chen; Qing Yu; Liang-Fu Jiang; Fei-Ya Zhou; Xiao-Yang Li; Jing-Quan Yang; Ting-Gang Chu; Wei-Yang Gao
Journal:  J Plast Reconstr Aesthet Surg       Date:  2009-07-18       Impact factor: 2.740

4.  RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.

Authors:  Hiroshi Nakamura; Shahid S Siddiqui; Xiang Shen; Asrar B Malik; Jose S Pulido; Nalin M Kumar; Beatrice Y J T Yue
Journal:  Mol Vis       Date:  2004-10-04       Impact factor: 2.367

Review 5.  Antifibrotics and wound healing in glaucoma surgery.

Authors:  Paul J Lama; Robert D Fechtner
Journal:  Surv Ophthalmol       Date:  2003 May-Jun       Impact factor: 6.048

6.  Inhibition of p38MAP kinase suppresses fibrogenic reaction in conjunctiva in mice.

Authors:  Osamu Yamanaka; Shizuya Saika; Yoshitaka Ohnishi; Shokei Kim-Mitsuyama; Anil K Kamaraju; Kazuo Ikeda
Journal:  Mol Vis       Date:  2007-09-18       Impact factor: 2.367

7.  Suppression of injury-induced conjunctiva scarring by peroxisome proliferator-activated receptor gamma gene transfer in mice.

Authors:  Osamu Yamanaka; Ken-ichi Miyazaki; Ai Kitano; Shizuya Saika; Yuji Nakajima; Kazuo Ikeda
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-24       Impact factor: 4.799

8.  Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.

Authors:  M F Cordeiro; A Mead; R R Ali; R A Alexander; S Murray; C Chen; C York-Defalco; N M Dean; G S Schultz; P T Khaw
Journal:  Gene Ther       Date:  2003-01       Impact factor: 5.250

9.  Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells.

Authors:  Baoliang Guo; Daisuke Koya; Motohide Isono; Toshiro Sugimoto; Atsunori Kashiwagi; Masakazu Haneda
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

10.  Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells.

Authors:  Huey-Chuan Cheng; Tsung-Chuan Ho; Show-Li Chen; Huei-Yi Lai; Kuo-Fu Hong; Yeou-Ping Tsao
Journal:  Mol Vis       Date:  2008-01-18       Impact factor: 2.367

View more
  4 in total

Review 1.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

2.  Rosiglitazone inhibits TGF-β 1 induced activation of human Tenon fibroblasts via p38 signal pathway.

Authors:  Yong-Heng Luo; Ping-Bo Ouyang; Jiao Tian; Xiao-Jian Guo; Xuan-Chu Duan
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

3.  Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation.

Authors:  Yi Gong; Jia-Yang Yin; Bo-Ding Tong; Jie-Xi Zeng; Wei Xiong
Journal:  Oncotarget       Date:  2017-10-09

4.  Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.

Authors:  Jun Bon Koo; Myeong-Ok Nam; Younshin Jung; Jongman Yoo; Duk Hwan Kim; Gwangil Kim; Sung Jae Shin; Kee Myung Lee; Ki Baik Hahm; Jong Woo Kim; Sung Pyo Hong; Kwang Jae Lee; Jun Hwan Yoo
Journal:  BMC Gastroenterol       Date:  2017-06-07       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.